alexa Therapeutic Vaccination In Chronic Infectious Diseases: The Place Of Vectored Vaccines
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Genevieve Inchauspe
Transgene SA, France
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-057
Abstract
Infectious pathogens resulting in chronicity have developed a wide array of strategies to hamper immune system of the infected host. These can involve immune-suppressive cytokines, activation of inhibitor pathways, T and B cells anergy and enhancing antibodies. The principal goal of therapeutic vaccination (so called active-targeted immune-therapeutic) is to complement the mechanism of action of standards-of-care (SOC) classically used in the treatment of chronic infection i.e., direct acting antivirals and antibiotics, by aiming at stimulating pathogen-specific, mostly T-cell based immunity, providing for the direct (cytolysis) or indirect (cytokine/ antibody-mediated) destruction of infected cells. Vectored-based vaccines using poxvirus and adenovirus backbones are particularly fit for the robust expression of sophisticated immunogenic sequences together with the signaling of innate immunity. Their combined used with SOC as well as newly developed anti-infective agents is today providing new treatment paradigms for the poorly curable or resistant infections. This presentation will introduce the general concepts in this field with specific examples in the development of vectored-therapeutic vaccines for the treatment of chronic hepatitis and Mycobacterium tuberculosis infections.
Biography

Geneviève Inchauspé has over 20 years of experience in academia occupying different positions at the interface between basic and clinical research before joining the industry (Transgene). She has developed a strong expertise in vaccinology, immunotherapy, immunology and virology through the conduct of studies in various animal models, including non-human primates. She has been driving the specific development of therapeutic vaccine candidates from pre-clinical to clinical development for hepatitis B and C (Phase 1 and 2).

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords